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ARTICLE
Endothelial LRP1 protects against
neurodegeneration by blocking cyclophilin A
Angeliki Maria Nikolakopoulou1*, Yaoming Wang1*, Qingyi Ma1*, Abhay P. Sagare1, Axel Montagne1, Mikko T. Huuskonen1,
Sanket V. Rege1, Kassandra Kisler1, Zhonghua Dai1, Jakob Körbelin2, Joachim Herz3,4, Zhen Zhao1**, and Berislav V. Zlokovic1**
The low-density lipoprotein receptor–related protein 1 (LRP1) is an endocytic and cell signaling transmembrane protein.
Endothelial LRP1 clears proteinaceous toxins at the blood–brain barrier (BBB), regulates angiogenesis, and is increasingly
reduced in Alzheimer’s disease associated with BBB breakdown and neurodegeneration. Whether loss of endothelial LRP1
plays a direct causative role in BBB breakdown and neurodegenerative changes remains elusive. Here, we show that LRP1
inactivation from the mouse endothelium results in progressive BBB breakdown, followed by neuron loss and cognitive deficits,
which is reversible by endothelial-specific LRP1 gene therapy. LRP1 endothelial knockout led to a self-autonomous activation
of the cyclophilin A–matrix metalloproteinase-9 pathway in the endothelium, causing loss of tight junctions underlying
structural BBB impairment. Cyclophilin A inhibition in mice with endothelial-specific LRP1 knockout restored BBB integrity and
reversed and prevented neuronal loss and behavioral deficits. Thus, endothelial LRP1 protects against neurodegeneration by
inhibiting cyclophilin A, which has implications for the pathophysiology and treatment of neurodegeneration linked to
vascular dysfunction.
Introduction
Low-density lipoprotein receptor–related protein 1 (LRP1) is a
transmembrane endocytic and cell signaling protein that regu-
lates diverse cellular functions in the brain, liver, kidney, lung,
and vasculature (Lillis et al., 2008; Gonias and Campana, 2014).
LRP1 was cloned and identified as an apolipoprotein E (apoE)
receptor (Herz et al., 1988) with a role in lipoprotein metabolism
(Lillis et al., 2008). Besides functioning as an endocytic receptor
for 100 diverse ligands, LRP1 binds different cell signaling
adapter and scaffold proteins via its cytoplasmic tail, interacts
with different receptors and plasma membrane proteins, and
activates signaling responses upon binding different ligands
(Lillis et al., 2008; Herz and Strickland, 2001; Bell et al., 2012;
Mantuano et al., 2013).
In the cerebral vascular system, endothelial LRP1 regulates
transendothelial clearance of several neurotoxins across the
blood–brain barrier (BBB), including Alzheimer’s amyloid-β
(Shibata et al., 2000; Deane et al., 2004; Yamada et al., 2008;
Zhao et al., 2015b; Winkler et al., 2015; Storck et al., 2016; Zhu
et al., 2018; Shin et al., 2019). It also controls angiogenesis in the
retina (Mao et al., 2016; Strickland and Muratoglu, 2016). Ad-
ditionally, endothelial LRP1 directly participates in gene tran-
scription in endothelial cells acting as a transcriptional coactivator
of the nuclear receptor PPARγ, a central regulator of lipid and
glucose metabolism, suggesting its role in maintaining energy
homeostasis (Mao et al., 2017).
Endothelial LRP1 is reduced by aging and is almost absent
from blood vessels in Alzheimer’s disease (AD) in humans
(Shibata et al., 2000; Deane et al., 2004; Donahue et al., 2006;
Halliday et al., 2016) and animal models (Deane et al., 2004;
Zhao et al., 2015b; Winkler et al., 2015; Jaeger et al., 2009). Its
loss is associated with BBB breakdown, which has been shown to
be an early biomarker of human cognitive dysfunction
(Montagne et al., 2015; Nation et al., 2019; Montagne et al., 2020)
and AD (Sweeney et al., 2018), and is also related to neuronal
dysfunction in animal models of AD (Zhao et al., 2015b; Winkler
et al., 2015). Whether loss of endothelial LRP1 plays a direct
causative role in BBB breakdown and neurodegenerative
changes remains, however, elusive. To address this question, we
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studied BBB integrity, neuronal phenotype, and behavior in an
endothelial-specific Lrp1 knockout line generated by crossing
Lrp1lox/loxmice (Boucher et al., 2003) with an endothelial-specific
Tie2-Cre line (Kisanuki et al., 2001).
Results
BBB breakdown and neuronal phenotype
Consistent with multiple previous independent reports dem-
onstrating expression of LRP1 protein in brain endothelial cells
by immunostaining, Western blotting, and/or immunogold
electron microscopy in different species, including mice, rats,
humans, bovines, and porcine (Shibata et al., 2000; Deane et al.,
2004; Yamada et al., 2008; Zhao et al., 2015b; Winkler et al.,
2015; Storck et al., 2016; Zhu et al., 2018; Shin et al., 2019; Mao
et al., 2016; Strickland and Muratoglu, 2016; Donahue et al.,
2006; Halliday et al., 2016; Jaeger et al., 2009; Wang et al., 2003;
Demeule et al., 2008; Ueno et al., 2010; Pflanzner et al., 2011; Gali
et al., 2019;Wu et al., 2020),we also showby immunoblotting with
an LRP1-specific antibody (Fig. 1 A) and quantitative real-time
PCR for Lrp1mRNA relative to Gapdh (housekeeping gene; Fig. 1,
B and C) that brain endothelial cells from Lrp1lox/lox littermate
control mice express both LRP1 protein and Lrp1mRNA. Of note,
brain endothelial cell cultures had typical cobblestone-like
shape and were positive for endothelial cell markers (includ-
ing von Willebrand factor, CD31, and vascular endothelial–
cadherin) and negative for pericyte markers (PDGFRβ, CD13,
and NG2), vascular smooth muscle cell markers (α-smooth
muscle actin), astrocyte markers (GFAP and AQP4), neuronal
markers (MAP2 and NeuN), and the microglia marker Iba1, as
we previously reported (Bell et al., 2012; Zhao et al., 2015b).
Compared with Lrp1lox/lox controls, brain endothelial cells from
Lrp1lox/lox; Tie2-Cre mice had complete deletion of LRP1 protein
and Lrp1 mRNA, as shown by immunoblotting (Fig. 1 A) and
quantitative real-time PCR (Fig. 1, B and C), respectively. Ad-
ditionally, we found gene dose–dependent loss of LRP1 and Lrp1
mRNA from brain endothelium in Lrp1lox/+; Tie2-Cre (lox/+) and
Lrp1lox/lox; Tie2-Cre (lox/lox) mice, respectively. In contrast,
brain capillary pericytes from Lrp1lox/+; Tie2-Cre (lox/+) and
Lrp1lox/lox; Tie2-Cre (lox/lox) mice expressed LRP1 protein and
Lrp1 mRNA at levels comparable to their Lrp1lox/lox littermate
controls (Fig. 1, D–F).
Expression of LRP1 in endothelium of brain capillaries iso-
lated from control Lrp1lox/lox mice, and its loss from endothelium
in Lrp1lox/lox; Tie2-Cre mice, was confirmed by triple immuno-
fluorescent staining for LRP1, the brain endothelial–specific
marker CD31, and the pericyte-specific marker CD13 (Fig. 1 G),
including the orthogonal views of different planes (xz, yz) of
higher magnification confocal images of LRP1 and CD31
(Fig. 1 H). Brain endothelial expression of LRP1 in Lrp1lox/lox mice
and its loss from endothelium in Lrp1lox/lox; Tie2-Cre mice were
independently confirmed using GLUT1 as another endothelial-
specific marker (Fig. 1 I).
First, we found that 2-mo-old Lrp1lox/lox; Tie2-Cremice develop
a spontaneous BBB breakdown, as illustrated by the presence
of the perivascular capillary deposits of blood-derived IgG
and fibrinogen in the cortex (Fig. 2 A). Quantification analysis
indicated that 2-mo-old Lrp1lox/lox; Tie2-Cre mice had in average
8–10 and 8–6 times greater accumulation of IgG and fibrinogen
deposits in the cortex and hippocampus, respectively, than their
Lrp1lox/lox littermate controls (Fig. 2, B and C). When compared
with 2-mo-old mice, 4-mo-old Lrp1lox/lox; Tie2-Cremice exhibited
a further increase in IgG and fibrinogen deposits (Fig. 2, B and
C). Progressive BBB breakdown in 2- and 4-mo-old Lrp1lox/lox;
Tie2-Cre mice compared with Lrp1lox/lox littermate controls has
been confirmed in vivo by two-photon imaging of intravenously
administered 40-kD FITC-dextran leakage from the cortical
capillaries (Fig. 2, D and E) and by tissue accumulation of in-
travenously administered Alexa Fluor 555–cadaverine (mol wt =
950 daltons), suggesting a substantial cortical uptake of this
tracer in mice with endothelial-specific LRP1 knockout (Fig. 2, F
and G).
At postnatal day P8, Lrp1lox/lox; Tie2-Cre mice had, however,
intact BBB to Alexa Fluor 555–cadaverine, showing no leakage of
this tracer into the cortex (Fig. S1 A, upper panel) or retina (Fig.
S1 A, lower panel), thus ruling out BBB breakdown during de-
velopment as a possible cause of BBB breakdown in adult
Lrp1lox/lox; Tie2-Cre mice. Additionally, Lrp1lox/lox; Tie2-Cre and
control mice had comparable cortical capillary length and
number of branching points (Fig. S1, B and C). Consistent with
these data, 2-mo-old Lrp1lox/lox; Tie2-Cre and control mice had
also comparable cortical capillary length (Fig. S1 D), suggesting
that there is no reduction in vascular density in these mice. In
contrast, we found that BBB breakdown in Lrp1lox/lox; Tie2-Cre
mice develops at earlier time points between P8 and 2 mo of
age (Fig. 2, A–G) and becomes detectable in 1-mo-old Lrp1lox/lox;
Tie2-Cre mice, as we shown by both fibrinogen deposits and
accumulation of intravenously administered Alexa Fluor 555–
cadaverine (Fig. S1, E and F).
Lrp1lox/lox; Tie2-Cre and control mice had similar cortical and
hippocampal capillary coverages of lectin+ endothelial profiles
by pericytes and/or astrocytic endfeet (Fig. S2, A–F). They also
expressed comparable levels of endothelial transporters known
to influence BBB integrity such as major facilitator superfamily
domain–containing protein 2 (Fig. S2, G and H; Ben-Zvi et al.,
2014) and glucose transporter 1 (Fig. S2, I and J; Winkler et al.,
2015). Thus, BBB breakdown as seen in Lrp1lox/lox; Tie2-Cre mice
could not be attributed to changes in pericyte and/or astrocyte
coverage or expression of other BBB-regulating transporters.
Next, we found that 2-mo-old Lrp1lox/lox; Tie2-Cre mice had
normal number of neurons and neuritic density, but at 4 mo of
age, they developed a substantial loss of NeuN+ neurons com-
pared with controls (∼30%) and loss of SMI312+ neurites (∼35%)
both in the cortex and hippocampus (Fig. 2, H–J), suggesting that
neuronal degeneration develops after BBB breakdown. Consis-
tent with these data, daily activity behavior tests burrowing and
nest building, and hippocampal memory tests novel object lo-
cation and recognition were normal in 2-mo-old Lrp1lox/lox; Tie2-
Cre mice, but all showed deficits in 4-mo-old Lrp1lox/lox; Tie2-Cre
mice compared with littermate controls (Fig. 2, K–N).
Brain endothelial LRP1 gene delivery
To test whether vascular and neuronal changes are reversible,
we performed a rescue experiment using brain endothelial–specific
Nikolakopoulou et al. Journal of Experimental Medicine 2 of 19
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adeno-associated viral construct (AAV2-BR1; Körbelin et al., 2016)
containing LRP1 minigene (mLRP1) with LRPIV (low-density lipo-
protein receptor–related protein cluster IV) extracellular domain and
the cytoplasmic cell signaling tail, as reported previously (Zhao et al.,
2015b). We chose to treat 3-mo-old Lrp1lox/lox; Tie2-Cre mice, be-
cause these mice have a pronounced BBB breakdown (Fig. 2, B,
C, E, and G) and begin developing a significant loss of neurons
(16–19%) and neuritic density (15–19%), respectively (Fig. S3).
AAV2-BR1-mLRP1 virus efficiently transduced brain endothelial
cells of Lrp1lox/lox; Tie2-Cre mice, as shown by >45% colocaliza-
tion of hemagglutinin (HA)–tagged mLRP1 with lectin+ endo-
thelial capillary profiles in the cortex and hippocampus (Fig. 3,
A and B). The transduction efficiency of mLRP1 was comparable
to previously shown brain endothelial transduction efficiency
of AAV2-BR1-GFP control vector (Körbelin et al., 2016). When
compared with GFP control, mLRP1 endothelial reexpression in
Lrp1lox/lox; Tie2-Cremice led to substantial reductions of IgG and
fibrinogen accumulates in the cortex and hippocampus (Fig. 3,
C–E). Quantification analysis revealed that Lrp1lox/lox; Tie2-Cre
mice treated with AAV2-BR1-mLRP1 had in average ∼55% and
54% reductions in IgG deposits (Fig. 3 D) and 58% and 55%
reductions in fibrinogen deposits (Fig. 3 E) in the cortex and
hippocampus, respectively, compared with the respective
leakages of IgG and fibrinogen in Lrp1lox/lox; Tie2-Cre mice
treated with the control AAV2-BR1-GFP construct. Reductions
in leakages of blood-derived proteins in Lrp1lox/lox; Tie2-Cremice
treated with AAV2-BR1-mLRP1 corresponded well with the
observed 45% transduction efficiency of mLRP1 (Fig. 3 B). A
higher magnification analysis indicated that vessel segments
that reexpressed HA-mLRP1 did not leak fibrinogen, whereas
those that did not reexpress HA-mLRP1 leaked fibrinogen
(Fig. 3 F).
Importantly, AAV2-BR1-mLRP1 treatment compared with
AAV2-BR1-GFP control increased the number of NeuN+ neuron
and SMI312+ neuritic density in the cortex and hippocampus of
Lrp1lox/lox; Tie2-Cre mice nearly to the levels seen in Lrp1lox/lox
littermate controls treated with AAV2-BR1-mLRP1 or control
AAV2-BR1-GFP virus (Fig. 3, G–I). When compared with AAV2-
BR1-GFP control treatment, gene therapy with mLRP1 also nor-
malized behavior in Lrp1lox/lox; Tie2-Cre mice on all four tests
almost to the levels found in Lrp1lox/lox littermate controls treated
with AAV2-BR1-mLRP1 or control AAV2-BR1-GFP virus (Fig. 3,
J–M). Since 3-mo-old Lrp1lox/lox; Tie2-Cre mice had a detectable
neuron loss (Fig. S3), these data suggest that the present mLRP1
gene therapy (1) restores the BBB integrity and lowers leakages
of blood-derived proteins to levels below those seen in 2-mo-old
Lrp1lox/lox; Tie2-Cre mice (Fig. 2, B and C) associated with normal
neuronal phenotype and behavior (Fig. 2, H–N) and (2) protects
mice from neuron loss and corrects behavioral deficits as shown
at 1 mo after treatment.
Activation of the cyclophilin A (CypA)–matrix
metalloproteinase-9 (MMP9) pathway
In search of a mechanism underlying BBB breakdown, we found
that 2-mo-old Lrp1lox/lox; Tie2-Cre mice compared with Lrp1lox/lox
littermate controls develop a substantial loss (>50%) of the en-
dothelial tight junction proteins zonula occludens 1 (ZO-1), oc-
cludin, and claudin 5, as shown by simultaneous immunostaining
for these tight junction proteins and endothelial-specific Lyco-
persicon esculentum lectin fluorescence staining (Fig. 4, A–D). Loss
of tight junction proteins was confirmed independently by im-
munoblotting of cortical microvessels isolated from these mice
(Fig. 4, E and F). Additionally, we found that mice with endo-
thelial knockout of LRP1 have greatly reduced levels of collagen
IV basement membrane protein and develop blood-derived
hemosiderin deposits indicative of microhemorrhages, as
shown by Prussian blue staining for iron (Fig. S4, A–D). Since
claudin 5 deficiency results in leakages of small, but not large,
tracers, as previously shown (Nitta et al., 2003), it is likely
that loss of several tight junction proteins as well as collagen
IV contributed to the observed BBB breakdown in Lrp1lox/lox;
Tie2-Cre mice.
Loss of endothelial tight junctions and collagen IV in
Lrp1lox/lox; Tie2-Cremice phenocopied the defects in mice lacking
murine apoE, an LRP1 ligand, and/or expressing human apoE4
(APOE4), which poorly interacts with LRP1 (Bell et al., 2012).
Apoe null mice and APOE4 knockin mice have normal levels of
LRP1 in endothelium, pericytes, and astrocytes but have an early
loss of cerebrovascular integrity because of a loss of signal
transduction (Bell et al., 2012; Fullerton et al., 2001) and/or weak
Figure 1. Endothelial LRP1 expression and deletion in mice. (A–C) LRP1 immunoblotting (#92544 mAb; Abcam; A), Lrp1mRNA quantitative real-time PCR
(B), and relative Lrp1 mRNA gene expression normalized to Gapdh (housekeeping gene; C) in brain endothelial cells cultured from Lrp1lox/lox littermate control
mice (control), Lrp1lox/+; Tie2-Cre (lox/+) and Lrp1lox/lox; Tie2-Cre (lox/lox) mice. In C, for relative gene expression calculations, we used the 2^(−ΔCt) method,
where Ct (cycle threshold) is defined as the number of cycles required for the fluorescent signal to cross the threshold (i.e., exceeds background level). With
respect to the ΔCt of the 2^(−ΔCt) method, ΔCt is the difference in the threshold cycles between Lrp1 and Gapdh genes. (D–F) LRP1 immunoblotting (D), Lrp1
mRNA quantitative real-time PCR (E), and relative Lrp1 mRNA gene expression normalized to Gapdh (F) in pericytes cultured from Lrp1lox/lox littermate control
mice (control), Lrp1lox/+; Tie2-Cre (lox/+), and Lrp1lox/lox; Tie2-Cre (lox/lox) mice. Calculations in F were the same as in C. (G) Representative confocal images of
triple immunofluorescent staining for LRP1, CD31 (endothelium), and CD13 (pericytes) showing expression of LRP1 in endothelium in isolated cortical capillaries
from Lrp1lox/lox control mice and its deletion from endothelium in capillaries from Lrp1lox/lox; Tie2-Cre (lox/lox) mice; purple, merged LRP1 and CD31 (endo-
thelium); yellow, merged LRP1 and CD13 (pericytes). No changes in expression of LRP1 in pericytes were observed between control and Lrp1lox/lox; Tie2-Cre (lox/
lox) mice. Scale bar = 10 µm. (H) High-magnification orthogonal views showing colocalization of LRP1 with endothelial marker CD31 in brain capillaries from
Lrp1lox/lox control mice (left) and loss of LRP1 from endothelium in brain capillaries from Lrp1lox/lox; Tie2-Cre mice (right). CD13, pericyte marker. Scale bar = 15
µm. (I) Representative confocal images of triple immunofluorescent staining for LRP1, GLUT1 (endothelium), and CD13 (pericytes) showing expression of LRP1
in endothelium in isolated cortical capillaries from Lrp1lox/lox control mice and its deletion from endothelium in capillaries from Lrp1lox/lox; Tie2-Cre (lox/lox) mice;
purple, merged LRP1 and GLUT1 (endothelium); yellow, merged LRP1 and CD13 (pericytes). No changes in expression of LRP1 in pericytes were observed
between control and Lrp1lox/lox; Tie2-Cre (lox/lox) mice. Scale bar = 10 µm. In C and F, significance was determined by one-way ANOVA followed by Bonferroni
post hoc test; ns, not significant; ****, P < 0.0001.
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signal transduction (Bell et al., 2012) between astrocyte-derived
apoE and human apoE4 with LRP1 on pericytes, respectively.
This in turn has been shown to lead to transcriptional activation
of the proinflammatory CypA–NF-κB–MMP9 pathway in peri-
cytes, causing non–cell-autonomousMMP9-mediated degradation
of tight junction proteins and collagen IV and leading to BBB
breakdown (Bell et al., 2012). Thus, we next studied whether
endothelial LRP1 deletion can lead to a cell-autonomous activation
of the CypA–MMP9 pathway in the endothelium. We found ele-
vated CypA and MMP9 levels in lectin+ endothelium in brain
Figure 2. BBB breakdown, neuron loss, and behavioral deficits after endothelial-specific Lrp1 deletion. (A) Immunostaining for IgG (left, purple), fi-
brinogen (right, purple), and lectin+ endothelium (green) shows perivascular capillary leakages of blood-derived proteins in the cortex of 2-mo-old Lrp1lox/lox;
Tie2-Cremice compared with Lrp1lox/lox littermate controls. Scale bar = 20 µm. (B and C) Quantification of IgG (B) and fibrin (C) deposits in the cortex (Ctx) and
hippocampus (Hp) in 2- and 4-mo-old Lrp1lox/lox; Tie2-Cre mice and Lrp1lox/lox controls. Mean ± SEM, n = 5 mice/group. (D and E) Capillary leakages of in-
travenously administered 40 kD FITC-dextran in the cortex of 2-mo-old Lrp1lox/lox; Tie2-Cremice compared with Lrp1lox/lox control mice (D), and quantification of
the BBB permeability–surface area product (PS) to 40 kD FITC-dextran in 2- and 4-mo-old mice (E). Scale bar = 50 µm. Mean ± SEM, n = 6 mice/group. (F and
G) Cortical uptake of intravenously administered Alexa Fluor 555–cadaverine (red) in 2-mo-old Lrp1lox/lox; Tie2-Cre and Lrp1lox/lox mice (F), and quantification of
cadaverine cortical uptake in 2- and 4-mo-old mice (G). Scale bar = 25 µm. White, lectin+ endothelium. Mean ± SEM, n = 5 mice/group. (H–J) NeuN+ neurons
and SMI312+ neurites (H), and quantification of NeuN+ neurons and SMI312+ neurites in the cortex and hippocampus in 2- and 4-mo-old Lrp1lox/lox; Tie2-Cre and
Lrp1lox/loxmice (I and J). Scale bar = 50 µm.Mean ± SEM, n = 5mice/group. (K–N) Burrowing (K), nest construction (L), novel object location (M), and recognition
(N) in 2- and 4-mo-old Lrp1lox/lox; Tie2-Cre and Lrp1lox/lox mice. Mean ± SEM, n = 12 (K and L) and n = 15–17 (M and N) mice/group. In B, C, E, G, and I–N,
significance was determined by one-way ANOVA followed by Bonferroni post hoc test; ns, not significant; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P <
0.0001. In B, C, E, and G, asterisks above red dots indicate comparisons with control group.
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Figure 3. Rescue of vascular and neuronal phenotype in Lrp1lox/lox; Tie2-Cremice by endothelial-specific LRP1 gene replacement. (A and B) Endothelial
expression of GFP (left, green), HA-tagged mLRP1 (right, green), and lectin+ endothelium (purple) in the cortex of 4-mo-old Lrp1lox/lox; Tie2-Cremice after AAV2-
BR1-GFP (left) or AAV2-BR1-mLRP1 (LRP1 minigene, right) treatment (A), and quantification of HA-mLRP1+ area colocalized with lectin+ endothelial capillary
profiles (<6 µm in diameter) in the cortex (Ctx) and hippocampus (Hp; B). Scale bar = 25 µm. Mean ± SEM; n = 3 mice/group. (C–E) IgG (left, purple) and
fibrinogen (right, purple) perivascular capillary deposits (C) and quantification (D and E) in 4-mo-old Lrp1lox/lox; Tie2-Cre and Lrp1lox/loxmice after AAV2-BR1-GFP
(top) or AAV2-BR1-mLRP1 (bottom) treatment. Green, lectin+ endothelium. Scale bar = 20 µm. Mean ± SEM, n = 14mice/group. (F) High-magnification confocal
images from Lrp1lox/lox; Tie2-Cremouse treated with AAV2-BR1-mLRP showing that vessel segments that reexpress HA-mLRP1 (asterisks) were no longer leaky
compared with a vessel segment that does not express HA-mLRP1 (arrow) that leaks fibrinogen. Scale bar = 10 µm. (G–I)NeuN+ neurons and SMI312+ neurites
(G) and quantification of NeuN+ neurons and SMI312+ neurites in the cortex and hippocampus of 4-mo-old Lrp1lox/lox and Lrp1lox/lox; Tie2-Cre mice after AAV2-
BR1-GFP (top panels) or AAV2-BR1-mLRP1 (bottom panels) treatment (H and I). Scale bar = 50 µm. Mean ± SEM, n = 14 mice/group. (J–M) Burrowing (J), nest
Nikolakopoulou et al. Journal of Experimental Medicine 6 of 19








f Edinburgh user on 16 M
arch 2021
microvessels from Lrp1lox/lox; Tie2-Cremice (Fig. 4 G, left), but not
in CD13+ pericytes (Fig. 4 G, middle and right). This correlated
with elevated Ppia (gene encoding CypA) andMmp9mRNA levels
in brain endothelial cells, but not in pericytes, from Lrp1lox/lox;
Tie2-Cremice (Fig. 4 H). Additionally, brain endothelial cells from
Lrp1lox/lox; Tie2-Cre mice compared with control mice had highly
elevated gelatinase activity that was inhibited by silencing
MMP9 with si.Mmp9, but not MMP2 with si.Mmp2, confirming
that increased gelatinase activity comes from elevated MMP9
(Fig. 4 I).
Inhibition of CypA by short interfering RNA to genetically
knock down Ppia (Fig. S4 E) or CypA pharmacologic inhibition
with cyclosporine A and inhibition of NF-κB with pyrrolidine
dithiocarbamate (PDTC) reduced by 75–80% Mmp9 mRNA
(Fig. 3 J) and activated MMP9 levels (Fig. 4 K) in brain endo-
thelial cells from Lrp1lox/lox; Tie2-Cre mice, suggesting a cell-
autonomous NF-κB–dependent transcriptional activation of
MMP9 by CypA. Adenoviral-mediated reexpression of mLRP1
(Ad.mLRP1; Fig. S4 F), but not control Ad.GFP, restored the
ability of murine apoE to transcriptionally suppress Ppia
(Fig. 4 L) and downstream Mmp9 mRNA (Fig. 4 M) and active
MMP9 levels (Fig. 4 N) in brain endothelial cells from Lrp1lox/lox;
Tie2-Cre mice, indicating that endothelial LRP1 maintains BBB
integrity by controlling the CypA–NF-κB–MMP9 pathway,
which requires apoE.
To find out whether CypA mediates BBB breakdown in
Lrp1lox/lox; Tie2-Cre mice in vivo, we next performed a proof-of-
concept study with cyclosporine A, a pharmacologic inhibitor of
CypA, to find out whether CypA inhibition can reverse BBB
breakdown in 2-mo-old Lrp1lox/lox; Tie2-Cremice.We chose 2-mo-
old mice because they develop BBB breakdown at that age but do
not have yet neuron loss or behavioral changes. We used a short-
term 7-d treatment with low-dose cyclosporine A starting with
10 mg/kg/d for 3 d followed by 5 mg/kg/d for the remaining 4 d,
because this short-duration low-dose regimen does not lead to
the systemic or central nervous system toxicity frequently seen
with longer duration treatments and higher doses of cyclo-
sporine A (see Materials and methods). Additionally, this dosing
regimen was previously shown to effectively reverse CypA-
driven BBB breakdown in transgenic APOE4 knockin mice
(Bell et al., 2012). Cyclosporine A reduced endothelial CypA and
MMP9 levels nearly to the levels seen in Lrp1lox/lox littermate
controls (Fig. S5, A–C), which led to substantial reductions in IgG
and fibrin perivascular accumulates in the cortex and hippo-
campus (Fig. S5, D–F) and recovery of tight junction proteins
and collagen IV (Fig. S5 G), suggesting that CypA inhibition can
reverse BBB phenotype even in the presence of endothelial
LRP1 loss.
Protection from neurodegeneration
Because cyclosporine A is an immunosuppressive CypA inhib-
itor, we next treated Lrp1lox/lox; Tie2-Cre mice with a
nonimmunosuppressive CypA inhibitor, Debio-025, previously
used in patients with hepatitis C (Stanciu et al., 2019) and mouse
models of muscular dystrophy and myopathy (Millay et al.,
2008; Tiepolo et al., 2009). Debio-025 was initiated in 3-mo-
old Lrp1lox/lox; Tie2-Cremice at 10 mg/kg/d i.p. for 30 d following
previous reports in mouse models of muscular dystrophy and
myopathy (Millay et al., 2008; Tiepolo et al., 2009). We started
Debio-025 at 3 mo of age, a time point when Lrp1lox/lox; Tie2-Cre
mice have a pronounced BBB breakdown (which we knew could
be reversed by CypA inhibition from the cyclosporine A ex-
periment above) and begin developing significant losses of
neurons and neuritic density (Fig. S3). The objective of this
experiment was to find out whether reversing BBB breakdown
with Debio-025 can stop and reverse and/or prevent develop-
ment of neuron loss and behavioral changes and protect from
neurodegeneration that we see in 4-mo-old mice lacking endo-
thelial LRP1.
After 30-d daily treatment with Debio-025, Lrp1lox/lox; Tie2-
Cre mice showed normalized MMP9 levels in the endothelium
(Fig. 5, A and B); remarkable reductions in fibrin and IgG ex-
travascular deposits (Fig. 5, C–E); restoration of the tight junc-
tion endothelial proteins ZO-1, occludin, and claudin 5 (Fig. 5,
F–I); and normalization of BBB permeability to gadolinium, as
shown by magnetic resonance imaging (MRI) in the cortex and
hippocampus (Fig. 5, J and K). Notably, Debio-025 compared
with vehicle protected Lrp1lox/lox; Tie2-Cre mice against neuro-
degeneration, as evidenced by increased number of NeuN+
neuron and SMI312+ neuritic density in the cortex and hippo-
campus nearly to the levels seen in Lrp1lox/lox littermate controls
treated with either Debio-025 or vehicle (Fig. 5, L–N). Compared
with vehicle, Debio-025 normalized behavior deficits in
Lrp1lox/lox; Tie2-Cre mice on all four tests close to the levels seen in
Lrp1lox/lox littermate controls treated with vehicle or Debio-025
(Fig. 5, O–R).
Discussion
The present study shows that (1) LRP1 inactivation in the endo-
thelium results in spontaneous disintegration of brain vasculature
by activating a self-autonomous CypA–MMP9 BBB-degrading
pathway in the endothelium causing loss of key endothelial
tight junction proteins (ZO-1, occludin, and claudin 5) and
collagen IV, which leads to structural impairment of the BBB;
(2) BBB breakdown resulting from loss of brain endothelial
LRP1 subsequently leads to loss of neurons and behavioral
deficits initiating neurodegenerative process related to leaked
blood-derived neurotoxic proteins, e.g., fibrinogen (Cortes-
Canteli et al., 2010; Montagne et al., 2018) and others (Bell
et al., 2010; Senatorov et al., 2019; Zhao et al., 2015a), as dis-
cussed below; (3) brain endothelial–specific in vivo LRP1 gene
therapy can reverse vascular phenotype and prevent and re-
verse neuron loss and behavioral deficits secondary to BBB
construction (K), novel object location (L), and recognition (M) in 4-mo-old Lrp1lox/lox; Tie2-Cre and Lrp1lox/lox mice after AAV2-BR1-GFP or AAV2-BR1-mLRP1
treatment. Mean ± SEM; n = 14 mice/group. In B, significance was determined by Student’s t test. In D, E, and H–M, significance was determined by one-way
ANOVA followed by Bonferroni post hoc test. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
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Figure 4. Activation of CypA-MMP9 pathway after Lrp1 endothelial loss. (A–D) ZO-1 (A, purple), occludin (B, purple), and claudin 5 (C, purple) coloc-
alization with endothelial lectin (green) in the cortex of 2-mo-old Lrp1lox/lox; Tie2-Cre mice and Lrp1lox/lox controls, and quantification of ZO-1, occludin, and
claudin 5 length on lectin+ endothelial profiles in these mice (D). Scale bar = 25 µm. Boxes in A–C are sites taken for higher magnification insets shown below
single and merged images, scale bar = 10 µm. Mean ± SEM, n = 5 mice/group. (E and F) Immunoblotting for ZO-1, occludin, and claudin 5 in brain capillaries (E)
Nikolakopoulou et al. Journal of Experimental Medicine 8 of 19
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breakdown; and (4) a nonimmunosuppressive CypA inhibitor,
Debio-25, can protect against neurodegeneration even in the
presence of LRP1 endothelial deficiency. These new findings
complement previously established functions of endothelial
LRP1 in regulating clearance of amyloid-β across the BBB
(Shibata et al., 2000; Deane et al., 2004; Yamada et al., 2008;
Zhao et al., 2015b; Winkler et al., 2015; Storck et al., 2016; Zhu
et al., 2018; Shin et al., 2019), angiogenesis in the retina (Mao
et al., 2016; Strickland and Muratoglu, 2016), and gene tran-
scription involved in lipid and glucose metabolism (Mao et al.,
2017).
Our earlier study (Halliday et al., 2016) showed that CypA
and MMP9 levels are increased in brain pericytes and endo-
thelium in postmortem human brain tissue from APOE4 carriers
diagnosed with AD, which was associated with BBB breakdown.
This study found that LRP1 levels in blood vessels were greatly
reduced in both APOE4 and APOE3 AD carriers. However, this
study did not show that loss of endothelial LRP1 leads to BBB
breakdown, nor did it make the link between loss of endothelial
LRP1 and neurodegeneration and neuron loss. Another earlier
study by our group (Bell et al., 2012) showed that the APOE gene
controls cerebrovascular integrity in mice by regulating CypA
expression in pericytes. Using APOE transgenic mice, this earlier
study demonstrated that APOE4, but not APOE3, leads to acti-
vation of the CypA–MMP9 pathway in pericytes in the presence
of normal levels of LRP1. This in turn leads to BBB breakdown,
followed by changes in the cortical activity determined by
voltage-sensitive dye imaging. However, whether APOE4
transgenic mice develop neuron loss and/or behavioral changes
has not been studied, and neither has the role of endothelial
LRP1 in maintaining the BBB and/or neuronal functions. In
contrast, the present study using an endothelial LRP1 knockout
line, brain endothelial–specific gene therapy with LRP1, and
pharmacological treatment with a nonimmunosuppressive
CypA inhibitor targeting the BBB endothelium has established
the link between loss of endothelial LRP1, neurodegeneration,
and behavior, which has not been studied by these earlier
reports.
A number of different LRP1 ligands, including apoE, α2-
macroglobulin (α2M), and others, might be affected by LRP1
endothelial inactivation. Since LRP1 is substantially reduced in
blood vessels in AD (Shibata et al., 2000; Deane et al., 2004; Zhao
et al., 2015b; Winkler et al., 2015; Donahue et al., 2006; Halliday
et al., 2016; Jaeger et al., 2009), its inactivation could potentially
lead to activation of the CypA–MMP9 pathway not only by
apoE4, as in APOE4 transgenic mice (Bell et al., 2012) and human
APOE4 carriers (Montagne et al., 2020), but also by apoE3, which
requires intact LRP1 to suppress this pathway (Bell et al., 2012).
Additionally, LRP1 endothelial loss may affect clearance of sol-
uble Aβ across the BBB either alone or complexed with apoE
and/or α2M, leading to retention of apoE-Aβ and α2M-Aβ
complexes in the brain. Excess Aβ, on the other hand, reduces
LRP1 levels in the brain endothelium by accelerating its
proteasome-dependent degradation (Deane et al., 2004), which
in turn can accelerate both Aβ-dependent and Aβ-independent
pathways of neurodegeneration. Besides these potential effects
of LRP1 endothelial deficiency, LRP1 global deficiency inhibits
Aβ generation and simultaneously impairs Aβ clearance, im-
plicating a more complex role for LRP1 than in BBB regulation
alone (Van Gool et al., 2019).
LRP1 also interacts with different membrane receptors, such
as Wnt receptor frizzled 1 (Zilberberg et al., 2004) and Notch3
(Meng et al., 2010), and therefore, its inactivation may disrupt
these signaling pathways. Interestingly, when subjected to a
high-fat diet, mice with endothelial-specific Lrp1 deletion display
a reduction in body weight, but when fed a normal chow diet,
they do not lose weight (Mao et al., 2017), as we also observed.
The present study did not find developmental changes in the
BBB in mice after endothelial-specific Lrp1 deletion. Why the
BBB remains intact shortly after birth remains presently un-
clear. It is possible, however, that there is an age-related change
in a key circulating or cell-autonomous gene that initiates the
BBB deficits at ∼1–2 mo of age, or it could be microbiome related
due to changes in gut microbiome after birth. Future studies
should explore these possibilities. Our data also show that BBB
breakdown in mice born with endothelial-specific Lrp1 deletion
occurs at 1–2 mo of age, which precedes neuronal changes that
are seen for the first time at 3 mo of age. However, it is possible
that deficient neurovascular coupling after 3 mo of age when
neuronal changes develop might leave active microvascular re-
gions more vulnerable to loss of endothelial LRP1, which can
contribute to accelerated BBB injury, as we see in mice with
endothelial-specific Lrp1 deletion at an older age of 4 mo.
Finally, wewould like to comment that∼20 studies suggested
expression of LRP1 in brain endothelial cells based on im-
munostaining, Western blotting, and/or immunogold electron
microscopy in mice, rats, humans, bovines, and porcine models
(Shibata et al., 2000; Deane et al., 2004; Yamada et al., 2008;
Zhao et al., 2015b; Winkler et al., 2015; Storck et al., 2016; Zhu
et al., 2018; Shin et al., 2019; Mao et al., 2016; Strickland and
and their relative abundance compared with β-actin (F) in Lrp1lox/lox; Tie2-Cre and Lrp1lox/lox mice. Mean ± SEM, n = 3 mice/group. β-actin, loading control.
(G) CypA, MMP9, and lectin+ endothelium (left: purple, CypA and lectin; white, MMP9 and lectin); CypA, lectin+ endothelium, and CD13+ pericytes (middle:
purple, CypA and lectin), and MMP9, lectin+ endothelium, and CD13+ pericytes (right: purple, MMP9 and lectin) in brain capillaries from Lrp1lox/lox; Tie2-Cre and
Lrp1lox/lox mice. Scale bar = 10 µm. (H) Ppia and Mmp9 mRNA relative abundance normalized to Gapdh (housekeeping gene) in brain endothelial cells and
pericytes from Lrp1lox/lox; Tie2-Cre and Lrp1lox/lox mice. Mean ± SEM, n = 5 isolates/group. (I) Gelatinase activity in brain endothelial cell medium from Lrp1lox/lox
and Lrp1lox/lox; Tie2-Cre mice with or without siMmp9 or siMmp2. AU, arbitrary units. Mean ± SEM, n = 4 isolates/group. (J and K) Inhibition of Mmp9mRNA (J)
and activated MMP9 (K) by CypA silencing (si.Ppia), the CypA inhibitor cyclosporine A (CsA; 42 nM), and the NF-κB inhibitor PDTC (20 µM) in brain endothelial
cells from Lrp1lox/lox; Tie2-Cremice. (L–N) Inhibition of PpiamRNA (L),Mmp9mRNA (M), and active MMP9 (N) in brain endothelial cells from Lrp1lox/lox; Tie2-Cre
mice after adenoviral LRP1 (Ad.mLRP1) reexpression in the presence of astrocyte-derived murine apoE (40 nM). AdGFP, control. Mean ± SEM, n = 3 isolates/
group. All mice were 2 mo old. In D and F, significance was determined by Student’s t test. In H–N, significance was determined by one-way ANOVA followed by
Bonferroni post hoc test. ns, not significant; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
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Figure 5. Cyclophilin A inhibitor Debio-025 reverses vascular phenotype and protects from neurodegeneration in Lrp1lox/lox; Tie2-Cremice. (A and B)
MMP9 immunoreactivity in cortical endothelium (A) and quantification (B) in Lrp1lox/lox; Tie2-Cremice after vehicle or Debio-025 treatment. Scale bar = 10 µm.
Mean ± SEM, n = 10 mice/group. (C–E) IgG and fibrin deposits in the cortex (C) and quantification of their deposits in the cortex (Ctx) and hippocampus (Hp; D
Nikolakopoulou et al. Journal of Experimental Medicine 10 of 19
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Muratoglu, 2016; Donahue et al., 2006; Halliday et al., 2016;
Jaeger et al., 2009; Wang et al., 2003; Demeule et al., 2008; Ueno
et al., 2010; Pflanzner et al., 2011; Gali et al., 2019; Wu et al.,
2020). Four studies using endothelial-specific Lrp1 knockout
mice have shown striking pathophysiological consequences of
LRP1 endothelial inactivation, including accumulation of Aβ
pathology (Storck et al., 2016), regulation of angiogenesis (Mao
et al., 2016), gene transcription (Mao et al., 2017), and, presently,
BBB breakdown and neurodegeneration. We also showed in the
present study by immunoblotting, quantitative real-time PCR,
and immunostaining that LRP1 is expressed in brain endothe-
lium in control mice. RNA sequencing (RNA-seq) studies using
bulk RNA-seq in mouse brain endothelial RiboTag-isolated cells
(Jambusaria et al., 2020) and human brain endothelial cells
(Zhang et al., 2016), and single-cell RNA-seq studies in mouse
brain endothelial cells (Zeisel et al., 2015; Sabbagh et al., 2018),
confirmed expression of Lrp1 in mice and LRP1 in humans at a
moderate number of copies but comparable to those found in
neurons, microglia, or oligodendrocytes. Other single-cell RNA-
seq studies of mouse endothelial cells showed a low to high
number of Lrp1 copies depending on the brain endothelial cell
subtype (Zeisel et al., 2018), a very low number of copies and
absence from some cells (Vanlandewijck et al., 2018), or even
complete absence (Kalucka et al., 2020). The reasons for the
discrepancies between different types of RNA-seq studies re-
main unclear at present. However, they could be attributed to
the differences in the methods used, type of tissue and cell
collection, number of cells analyzed, and/or number of reads.
Additionally, it is worth mentioning that the steady-state levels
of proteins may or may not reflect rates of transcription. For
example, a comparison of subunit stoichiometry and ribosome
profiling versus RNA-seq reads has shown that RNA does not
reflect at all subunit stoichiometry, while the translational
landscape does (Li et al., 2014).
In summary, we show that endothelial LRP1 protects BBB
integrity and the brain against neurodegeneration by sup-
pressing CypA activation in the endothelium. This is of partic-
ular interest for neurodegenerative disorders associated with
vascular dysfunction and cognitive decline and loss of endo-
thelial LRP1, such as AD (Sweeney et al., 2018). Previous studies
have shown that BBB breakdown leads to leakages into brain
parenchyma of several neurotoxic blood-derived proteins, such
as albumin (Senatorov et al., 2019), thrombin, plasminogen and/
or iron-containing proteins (Bell et al., 2012, 2010), or fibrinogen
(Cortes-Canteli et al., 2010; Montagne et al., 2018), that all can
initiate neurodegenerative changes and neuron loss by different
but complementary mechanisms. The present study also shows
that endothelial LRP1 gene replacement therapy or CypA inhi-
bition in the presence of endothelial LRP1 loss can reverse vas-
cular phenotype and prevent and/or reverse development of
neurodegenerative changes. These findings have implications
both for the pathophysiology and treatment of neurodegeneration
linked to vascular dysfunction.
Materials and methods
Animals
Mice were housed in plastic cages on a 12-h light cycle with ad
libitum access to water and a standard laboratory diet. All pro-
cedures were approved by the Institutional Animal Care and Use
Committee at the University of Southern California with Na-
tional Institutes of Health guidelines. Lrp1lox/lox mice were kindly
provided by Dr. J. Herz at UT Southwestern Medical Center
(Dallas, TX; Boucher et al., 2003) and crossed with an endothelial-
specific Tie2-Cre line (Kisanuki et al., 2001) to generate Lrp1lox/lox;
Tie2-Cre mice with endothelial-specific LRP1 deletion. All animals
were genotyped by PCR using protocols and primer sequences as
described by the distributor or donating investigator. Animals of
both sexes at P8 and 2 and 4 mo of age were used in the experi-
ments. All animals were included in the study. All animals were
randomized for their genotype information. All experiments were
blinded; the operators responsible for the experimental proce-
dures and data analysis were blinded and unaware of group al-
location throughout the experiments.
Treatments
Brain endothelial cell–specific AAV2-BR1-mLRP1 therapeutic vector
For the rescue experiment, 3-mo-old Lrp1lox/lox; Tie2-Cre mice
were administered intravenously with adeno-associated AAV2-
BR1-mLRP1 vector or AAV2-BR1-GFP control construct. We chose
to treat 3-mo-old Lrp1lox/lox; Tie2-Cre mice, because at this age,
these mice develop a pronounced BBB breakdown and moderate
but significant neuronal damage. To this end, the previously
reported LRP1 minigene (mLRP1) containing the LRPIV extra-
cellular domain and the intracellular cytoplasmic domain of the
human LRP1 gene (Bell et al., 2012; Zhao et al., 2015b) was
packaged into brain microvascular endothelial-specific AAV2-
BR1 vector particles (Körbelin et al., 2016). Surgical procedures
and E) in Lrp1lox/lox and Lrp1lox/lox; Tie2-Cremice after vehicle or Debio-025 treatment. Scale bar = 20 µm. Mean ± SEM, n = 14mice/group. (F–I) ZO-1 (F, purple),
occludin (G, purple), and claudin 5 (H, purple) colocalization with endothelial lectin (green) in the cortex of 4-mo-old Lrp1lox/lox; Tie2-Cre mice treated with
vehicle or Debio-25, and quantification of ZO-1, occludin, and claudin 5 length on lectin+ endothelial capillary profiles in these mice (I). Scale bar = 25 µm. Boxes
in F–H are sites taken for higher magnification insets shown below single and merged images. Scale bar = 10 µm. White (merged), colocalization of ZO-1,
occludin, or collagen with lectin. Mean ± SEM, n = 5 mice/group. (J and K) BBB Ktrans maps (J) and Ktrans values in the cortex and hippocampus (K) in Lrp1lox/lox;
Tie2-Cremice after vehicle or Debio-025 treatment, compared with Lrp1lox/loxmice treated with vehicle. Scale bar = 0.5 mm. Mean ± SEM, n = 5–6 mice/group.
(L–N) NeuN+ neurons and SMI312+ neurites (L) and quantification of NeuN+ neurons and SMI312+ neurites in the cortex and hippocampus (M and N) in 4-mo-
old Lrp1lox/lox and Lrp1lox/lox; Tie2-Cremice after vehicle or Debio-025 treatment. Scale bar = 50 µm. Mean ± SEM, n = 14 mice/group. (O–R) Burrowing (O), nest
construction (P), novel object location (Q), and recognition (R) in Lrp1lox/lox and Lrp1lox/lox; Tie2-Cremice after vehicle or Debio-025 treatment. Mean ± SEM, n =
14 mice/group. All mice were 4 mo old. Debio-025 (10 mg/kg/d) or vehicle were given for 30 d starting at 3 mo of age. In B, significance was determined by
Student’s t test. In D, E, I, K, and M–R, significance was determined by one-way ANOVA followed by Bonferroni post hoc test. *, P < 0.05; **, P < 0.01; ***, P <
0.001; ****, P < 0.0001.
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were performed under general anesthesia with isoflurane
(1–1.5%) using the SomnoSuite Small Animal Anesthesia System
(Kent Scientific). Rectal temperature was monitored and main-
tained at 36.5 ± 0.5°C. AAV2-BR1-mLRP1 or AAV2-BR1-GFP
constructs were injected through the tail vein at a dose of 2 × 1011
gp/mouse that has been shown previously to lead to a successful
gene transfer to the brain endothelia with AAV2-BR1 serotype
(Körbelin et al., 2016). Tissue and behavior analyses were per-
formed at 4 mo of age.
Cyclosporine A proof-of-concept study
First, we performed a proof-of-concept study with cyclosporine
A (Sadimmune, 50 mg/ml, dissolved in sterile 0.9% saline; No-
vartis), a pharmacologic inhibitor of CypA, to find out whether
CypA inhibition can reverse BBB breakdown in 2-mo-old
Lrp1lox/lox; Tie2-Cre mice. We chose 2-mo-old mice because they
develop BBB breakdown but do not yet have neuronal loss or
behavioral changes. We used a short-term 7-d treatment with
low-dose cyclosporine A starting with 10 mg/kg/d for 3 d fol-
lowed by 5 mg/kg/d for the remaining 4 d, because it has been
previously shown that this short-duration low-dose regimen (1)
does not lead to systemic or central nervous system toxicity
frequently seen with longer duration treatments and with
higher doses of cyclosporine A (Famiglio et al., 1989; Santos and
Schauwecker, 2003; Lim et al., 2013) and (2) effectively reverses
CypA-driven BBB breakdown in transgenic APOE4 knockin mice
(Bell et al., 2012).
Treatment with Debio-025
Because cyclosporine A is an immunosuppressive CypA inhibi-
tor, we next studied Debio-025 (catalog number HY-12559;
MedChem Express), a nonimmunosuppressive CypA inhibitor
that has been used in humans for nonneurological indications
such as hepatitis C (Stanciu et al., 2019). Debio-025 was initiated
in 3-mo-old Lrp1lox/lox; Tie2-Cre mice at 10 mg/kg/d i.p. for 30 d
following previous reports in mouse models of muscular dys-
trophy and myopathy (Millay et al., 2008; Tiepolo et al., 2009).
We started Debio-025 at 3 mo of age, when Lrp1lox/lox; Tie2-Cre
mice have a pronounced BBB breakdown (which we knew could
be reversed by CypA inhibition from the cyclosporine A ex-
periment) and moderate but significant loss of neurons and
neuritic density. The objective of this experiment was to find out
whether reversing BBB breakdown with Debio-025 can prevent
development of neuron loss and behavioral changes that we see
in 4-mo-old mice lacking endothelial LRP1.
In vitro studies
Isolation of brain capillaries
Brain capillaries were isolated using dextran gradient centrifu-
gation followed by sequential cell-strainer filtrations, as we have
previously described (Bell et al., 2012). Briefly, cerebral cortices
devoid of cerebella, white matter, and leptomeninges were
prepared and cut into small pieces in ice-cold PBS containing 2%
FBS and then homogenized by a Dounce tissue grinder (0.25 mm
clearance) with approximately five strokes. Dextran (70 kD;
Sigma) was subsequently added to yield a final concentration of
16%, and the samples were thoroughly mixed. The samples were
then centrifuged at 6,000 g for 15min. Themicrovessel-depleted
brain (brain tissue minus capillaries) remained on top of the
dextran gradient, and the capillary pellet located at the bottom of
the tubes was collected and sequentially filtered through a 100-
µm and 45-µm cell strainer (BD Falcon). The capillaries re-
maining on top of the 45-µm cell strainer were collected in PBS
and lysed for immunoblot analysis, cytospun for immunofluo-
rescent staining analysis, or processed to establish primary en-
dothelial and pericyte cell cultures as described below.
Brain endothelial cell culture
Primary mouse brain endothelial cells were isolated and cul-
tured as we and others previously described (Zhao et al., 2015b;
Ruck et al., 2014). Briefly, isolated brain microvessels were re-
suspended in 9 ml DMEM plus 1 ml collagenase/dispase (final
concentration is 1 mg/ml) and 0.1 ml DNase I (1 mg/ml in PBS)
and digested for 1 h at 37°C on an orbital shaker at 180 rpm. The
cells were centrifuged at 1,000 g for 12 min, and the pellet was
resuspended in 10 ml of complete culture medium (catalog
number M1168; Cell Biologics; containing 5% FBS, 1% nones-
sential amino acids, 1% vitamins and endothelial cell growth
supplement comprising vascular endothelial growth factor,
heparin, and epidermal growth factor), plated in a T25 tissue
culture flask precoated with collagen IV (0.4 mg/ml) and 100 µl
fibronectin (0.1 mg/ml), and cultured at 37°C with 5% CO2 in a
humidified incubator. After 6–12 h, the nonadherent cells were
rinsed away, and fresh medium was replaced every 2–3 d until
the cell population became confluent. Cultures were confirmed
to be morphologically consistent with primary endothelial cul-
tures with cobblestone-like shape and positive for endothelial
markers, including von Willebrand factor, CD31, and vascular
endothelial–cadherin. Cultures were negative for the pericyte
markers PDGFRβ, CD13, and NG2; vascular smooth muscle cell
markers, including α-smooth muscle actin; the astrocyte mark-
ers GFAP and AQP4; the neuronal markersMAP2 and NeuN; and
the microglia marker Iba1, as we previously reported (Bell et al.,
2012; Zhao et al., 2015b). siRNA transfections were performed
using Lipofectamine RNAiMAX Reagent (Thermo Fisher Scien-
tific) following the manufacturer’s instructions, as we previ-
ously reported (Zhao et al., 2015b).
Adenoviral-mediated reexpression of mLRP1 in brain
endothelial cells
In a subset of experiments, primary brain endothelial cells iso-
lated from 2-mo-old Lrp1lox/lox; Tie2-Cre mice were placed in 12-
well plates and incubated with Ad.mLRP1 or Ad.GFP adenovirus
at concentration of 107 PFU/ml. Cells were harvested 72 h after
virus transduction for LRP1 minigene Western blot analysis
using anti-HA tag antibody (catalog number 372S; Cell Signaling
Technology).
DQ-gelatin degradation assay
The gelatinolytic activity of matrix metalloproteases was de-
termined in the conditioned medium from brain endothelial cell
cultures from 2-mo-old Lrp1lox/lox; Tie2-Cre mice and Lrp1lox/lox
littermate controls using DQ-Gelatin (D-12054; Invitrogen) assay
as reported (Vandooren et al., 2011). Four independent primary
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mouse brain endothelial cell cultures (200,000 cells/well, four
wells per culture) were used for all studied conditions. For
MMP2 and MMP9 knockdown, Accell Mmp2 siRNA (E-047467-
00-0010; Dharmacon) and Accell Mmp9 siRNA (E-065579-00-
0010; Dharmacon) at a final concentration of 1 µM in Accell
siRNA DeliveryMedia (B-005000-500; Dharmacon) were added
into 90% confluent cultures and incubated for 72 h. The condi-
tioned medium was then collected, centrifuged, and incubated
with DQ-Gelatin in a 96-well plate, and the fluorescence was
measured at 485/530-nm excitation/emission wavelengths us-
ing a fluorescence reader (Victor 3; Perkin Elmer).
Active MMP9
Active MMP9 was determined in brain endothelial cell cultures
using a previously described method (Aleksinskaya et al., 2013).
Briefly, primary brain endothelial cells from 2-mo-old Lrp1lox/lox;
Tie2-Cre mice with silenced CypA (si.Ppia) or si.Control, in the
presence of the CypA inhibitor cyclosporine A and the NF-κB
inhibitor PDTC, and after adenoviral LRP1 (Ad.mLRP1) re-
expression or control Ad.GFP in the presence of astrocyte-
derived murine apoE, were harvested for mouse MMP9
activity assay (QuickZyme). MMP9 was captured by a mouse-
specific antibody, and its activity was detected based on
cleavage of chromogenic substrates as measured at 405 nm
using an ELISA plate reader.
Brain pericyte culture
Primary mouse brain pericytes were isolated for in vitro cul-
turing as we previously described (Sagare et al., 2013). Briefly,
isolated microvessel fragments were digested for 12 h at 37°C
with collagenase A (10103586001; Roche) with constant shaking
and vigorous pipetting every 3–4 h. The cells were then spun
down andwashedwith PBS and then plated in completemedium
containing DMEM, 10% FBS, 1% nonessential amino acids, 1%
vitamins, and 1% antibiotic/antimycotic on plastic (noncoated)
tissue culture plates. After 6–12 h, the nonadherent cells were
rinsed away, and fresh medium was replaced every 2–3 d. Cul-
tures were confirmed to be morphologically consistent with
pericyte cultures and were positive for the pericyte markers
PDGFRβ, CD13, NG2, and desmin. Cultures were negative for the
endothelial markers von Willebrand factor and CD31, the as-
trocyte markers GFAP and AQP4, the neuronal markers MAP2
and NeuN, and the microglia marker Iba1, as we previously re-
ported (Bell et al., 2012).
Western blotting
All samples (isolated brain capillaries, endothelial cells, and
pericytes) from Lrp1lox/lox; Tie2-Cre mice and Lrp1lox/lox lit-
termate controls were lysed in RIPA buffer (50mMTris, pH 8.0,
150mMNaCl, 0.1% SDS, 1.0%NP-40, 0.5% sodium deoxycholate,
and protease inhibitor cocktail; Roche). Samples were then
subjected to SDS-Page gel electrophoresis and transferred to a
nitrocellulose membrane. Membranes were blocked with 5%
milk, incubated with the following primary antibodies: rabbit
anti–ZO-1 (catalog number 40–2200, 1:1,000; Invitrogen), rabbit
anti-occludin (catalog number16453, 1:500; BD Biosciences),
rabbit anti–claudin-5 (catalog number ab15106, 1:1,000; Abcam),
rabbit anti–GLUT-1 (CBL242, 1:500; Millipore), and rabbit anti-
human MFSD2A (catalog number A18288, 1:1,000; ABclonal).
They were then incubated with HRP-conjugated donkey anti-
rabbit secondary antibody (catalog number A16029, 1:5,000;
Invitrogen). Membranes were then treated with SuperSignal
West Pico PLUS chemiluminescent substrate (Thermo Fisher
Scientific). For Fig. 1, A and D, we used a digital chemilumi-
nescence imaging system (ChemiDoc MP, Universal Hood III;
Bio-Rad) to capture images as .tiff files using Image Lab 6.0.1
software. For all other figures, treated membranes were exposed
to CL-XPosure film (Thermo Fisher Scientific) and developed in
a X-OMAT 3000 RA film processor (Kodak) or ChemiDoc XRS
system from Bio-Rad.
RNA extraction and quantitative real-time PCR
RNA extraction from brain endothelial cells and pericyte cul-
tures from Lrp1lox/lox; Tie2-Cre mice and Lrp1lox/lox littermate
controls was performed using the SV Total RNA Isolation kit
(catalog number Z3100; Promega) following the manufacturer’s
instructions. 100 ng total RNA was used as template for quan-
titative real-time PCR, and amplification was performed using
qScript One-Step quantitative real-time PCR kit (catalog number
95057–050; Quanta Biosciences). To examine mRNA expression
of Lrp1 (forward: 59-ACTATGGATGCCCCTAAAACTTG-39, re-
verse: 59-GCAATCTCTTTCACCGTCACA-39) and Gapdh (forward:
59-AGGTCGGTGTGAACGGATTTG-39, reverse: 59-TGTAGACCA
TGTAGTTGAGGTCA-39), specific forward and reverse primers
were used. Data were analyzed by normalizing the expression of
Lrp1 to Gapdh (housekeeping gene) within endothelial cells and
pericytes. For relative gene expression calculations, we used the
2^(−ΔCt) method, where Ct (cycle threshold) is defined as the
number of cycles required for the fluorescent signal to cross
the threshold (i.e., exceeds background level). With respect to the
ΔCt of the 2^(−ΔCt) method, ΔCt is the difference in the threshold
cycles between Lrp1 and Gapdh genes.
Immunohistochemistry
Animals were anesthetized with an i.p. injection of 100 mg/kg
ketamine and 10 mg/kg xylazine and transcardially perfused
first with 15 ml saline, followed by 20 ml of 4% paraformalde-
hyde (PFA) in PBS. Brains were removed and postfixed over-
night with 4% PFA at 4°C before brain sections were cut at 30 µm
thickness. Retinas from P8 mice were processed as previously
described (Trost et al., 2013). Cytospins from isolated micro-
vessels were fixed with 4% PFA for 10 min at room temperature
and subsequently washed three times in PBS. Tissue sections
were blocked with 5% normal donkey serum (Vector Laborato-
ries)/0.1% Triton-X/0.01 M PBS and incubated with primary
antibodies diluted in blocking solution overnight at 4°C. All
primary and secondary antibodies are listed in Table S1. To vi-
sualize brain microvessels, sections were incubated with Dylight
488–, 594–, or 647–conjugated L. esculentum lectin (Vector Lab-
oratories) as we have previously reported (Zhao et al., 2015b;
Bell et al., 2010). After incubation with primary antibodies,
sections were washed in PBS and incubated with fluorophore-
conjugated secondary antibodies (see Table S1) and then
mounted onto slides with DAPI fluorescence mounting medium
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(Dako). Sections were imaged with a Zeiss LSM 510 confocal
laser-scanning microscope using a series of high-resolution
optical sections (1,024 × 1,024-pixel format) that were cap-
tured with a 25× water-immersion objective with 1× zoom at
1-µm step intervals for z-stacks. Laser settings for gain, digital
offset, and laser intensity were kept standardized between
different treatments and experiments. Z-stack projections and
pseudocoloring were performed using ZEN software (Carl Zeiss
Microimaging). Postanalysis imaging was performed using
ImageJ software.
Quantification analysis
For quantification of extravascular leakages, NeuN+ neuronal
nuclei, neurofilament SMI-312+ axons, tight junction protein,
and collagen IV length, pericyte, aquaporin-4, and syntrophin
coverages of brain capillary lectin+ endothelial profiles (micro-
vessels <6 µm in diameter), CypA, MMP9, and HA-mLRP1 im-
munoreactivity in brain capillary (<6 µm in diameter) lectin+
endothelium, four to six randomly selected fields per animal in
the somatosensory cortex region and/or CA1 region of the hip-
pocampus were analyzed in three or four nonadjacent sections
(∼100 µm apart) and averaged per mouse. The image area an-
alyzed was 640 × 480 µm. The number of animals used for each
analysis is indicated in the respective figure legends.
Extravascular leakages
Blood-derived fibrin(ogen) and IgG perivascular capillary de-
posits in the cortex and hippocampus were quantified as we
previously described (Sagare et al., 2013; Bell et al., 2010;
Winkler et al., 2015). Briefly, for quantification of extravascular
fibrinogen deposits, an antibody that detects both fibrinogen
and fibrinogen-derived fibrin polymers was used. 10-μm max-
imum projection z-stacks were reconstructed, and the fibrino-
gen extravascular signal on the abluminal side of lectin+
endothelial profiles on brain capillaries (<6 µm in diameter) was
analyzed using ImageJ (Bell et al., 2010). A similar approach was
used to quantify IgG deposits.
NeuN+ neuronal nuclei
10-μm maximum projection z-stacks were reconstructed, and
NeuN+ neurons in the cortex and hippocampus were quantified
using the ImageJ Cell Counter analysis tool as we previously
described (Bell et al., 2010; Nikolakopoulou et al., 2019).
Neurofilament SMI-312+ axons
As we previously described (Bell et al., 2010; Nikolakopoulou
et al., 2019), 10-μm maximum projection z-stacks were re-
constructed, and SMI-312+ signal in the cortex and hippocampus
was subjected to threshold processing and analyzed using
ImageJ. The areas occupied by the signal were then analyzed
using the ImageJ area measurement tool. Total SMI-312+ area
was expressed as a percentage of total brain area in each field.
Tight junction proteins and collagen IV
The length of ZO-1+, occludin+, and claudin 5+ immunofluores-
cent signals on lectin+ endothelial brain capillary profiles (<6 µm
in diameter) in the cortex was determined using the ImageJ area
measurement tool and expressed in millimeters of ZO-1, occlu-
din, and claudin 5 length per square millimeter of the area of
brain capillary lectin+ endothelial profiles (<6 µm in diameter).
A similar approach was used to quantify collagen IV length.
Pericyte coverage of brain capillaries
10-μm maximum projection z-stacks were reconstructed, and
the areas occupied by CD13+ pericyte on brain capillary lectin+
endothelial profiles (<6 µm in diameter) were analyzed using
ImageJ as we previously described (Nikolakopoulou et al.,
2017).
Astrocyte coverage of brain capillaries with aquaporin 4
10-μm maximum projection z-stacks were reconstructed, and
the areas occupied by aquaporin 4+ astrocyte endfeet on brain
capillary lectin+ endothelial profiles (<6 µm in diameter) were
analyzed using ImageJ as we previously described (Nikolakopoulou
et al., 2019).
Astrocyte coverage of brain capillaries with syntrophin
10-μm maximum projection z-stacks were reconstructed, and
the areas occupied by syntrophin+ astrocyte endfeet on brain
capillary lectin+ endothelial profiles (<6 µm in diameter) were
analyzed using ImageJ as we previously described (Nikolakopoulou
et al., 2019).
CypA endothelial immunofluorescent detection
The CypA+ area occupying brain capillary lectin+ endothelial
profiles (microvessels <6 µm in diameter) was determined
using immunofluorescent detection and expressed as a per-
centage of brain capillary lectin+ endothelial area using the
ImageJ area measurement tool as we previously described
(Bell et al., 2012).
MMP9 endothelial immunofluorescent detection
The MMP9+ area occupying brain capillary lectin+ endothelial
profiles (microvessels <6 µm in diameter) was determined
using immunofluorescent detection and expressed as a per-
centage of brain capillary lectin+ endothelial area using the
ImageJ area measurement tool as we previously described
(Bell et al., 2012).
HA-mLRP1 expression in endothelium after AAV2-BR1-mLRP1
treatment
The HA-mLRP1+ area occupying brain capillary lectin+ endo-
thelial profiles (microvessels <6 µm in diameter) in Lrp1lox/lox;
Tie2-Cre mice after AAV2-BR1-mLRP1 treatment was expressed
as a percentage of brain capillary lectin+ endothelial area using
the ImageJ area measurement tool as we previously described
(Bell et al., 2012).
Microvascular length and branching points
Total length and branching points of microvessels (<6 µm in
diameter) were manually quantified using ImageJ plugins, in-
cluding NeuronJ for microvessel length and Cell Counter for
branching points, and expressed as per square millimeter of
tissue, as previously reported (Ma et al., 2013).
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LRP1 endothelial expression in freshly isolated brain capillaries
Triple immunostaining for LRP1 (rabbit anti-human LRP1
[EPR3724], ab92544; 1:100; Abcam), CD13 (AF2335; 1:100; R&D
Systems) for pericytes, and the endothelial-specific markers
CD31 (550274; 1:100; BD PharMingen) or GLUT1 (Alexa Fluor
594–conjugated, ab206360; 1:200; Abcam) was performed on
isolated brain capillaries (cytospins) from Lrp1lox/lox control mice
and Lrp1lox/lox; Tie2-Cremice to confirm LRP1 expression in brain
capillary endothelium in control mice and its deletion from
endothelium in LRP1 endothelial-specific knockout mice. Sec-
ondary antibodies were Alexa Fluor 488–conjugated donkey
anti-rabbit (A-21206; 1:500; Invitrogen) for LRP1-positive cells,
Alexa Fluor 594–conjugated goat anti-rat (A-11007; 1:500; In-
vitrogen) for CD31+ endothelium, and Alexa Fluor 647–
conjugated donkey anti-goat (A-21447; 1:500; Invitrogen) for
CD13+ pericytes. Orthogonal projection views of confocal images
of LRP1 with endothelial marker CD31 showing expression of
LRP1 in brain capillary endothelium in Lrp1lox/lox control mice,
and loss of LRP1 from endothelium in brain capillaries from
Lrp1lox/lox; Tie2-Cre mice, were generated from 20 single-plane
maximum projection intensity z-stacks using ImageJ.
Brightfield microscopy
Prussian blue staining was performed using the Iron Stain Kit
(HT-20) per the manufacturer’s instructions, as we previously
described (Bell et al., 2012, 2010). For quantification of Prussian
blue–positive hemosiderin deposits, a minimum of six nonad-
jacent coronal cortical sections (∼100 µm apart) per mouse were
analyzed. The mean number of Prussian blue–positive hemo-
siderin deposits per animal was expressed per square millimeter
of tissue. For counterstain, sections were stained with Cresyl
Violet per the manufacturer’s instructions (Cresyl Violet Stain
Solution, 0.1%, ab246816; Abcam).
Cranial window
Animals were initially anesthetized with 100 mg/kg ketamine
and 10 mg/kg xylazine and placed on a heating pad (37°C). The
cranium of the mouse was firmly secured in a stereotaxic frame
(Kopf Instruments). A high-speed dental drill (tip FST 19007–05;
Fine Science Tools) was used to thin a cranial window ∼5 mm in
diameter over the somatosensory cortex, and 45° forceps were
used to remove the piece of skull. Gelfoam (Pharmacia & Up-
john) was applied immediately to control any cranial or dural
bleeding. A sterile 5-mm glass coverslip was then placed on the
dura mater and sealed with cyanoacrylate-based glue.
In vivo two-photon imaging of BBB permeability to
FITC-dextran
For BBB permeability measurements of FITC-dextran (40 kD)
leakage from cortical microvessels, mice were anesthetized with
isoflurane, fixed in a stereotaxic frame (Kopf Instruments) un-
der a two-photon microscope (with 20×, 1.0 NA objective), and
maintained at 1.2% isoflurane throughout the experiment. Body
temperature was maintained at 37°C with a homeothermic
heating pad. In vivo images were acquired using a custom-built
Zeiss LSM 5MP multiphoton microscope coupled to a mode
locked Ti/sapphire laser (Mai Tai Deep See; Spectra Physics) set
to 800 nm. FITC emission was collected using a 500–550 nm
bandpass filter. Immediately before image acquisition, the vas-
culature was labeled via retro-orbital injection of 40 kD FITC-
dextran dye (0.1 ml of 10 mg/ml: Thermo Fisher Scientific).
FITC-dextran–labeled vasculature and diffusion (leakage) of
FITC-dextran from cortical capillaries into the parenchyma was
imaged through the cranial window every 5 min for 30min. The
imaging depth was 200 µm, and the images acquired did not
include pial vessels. Leaky microvessels were mainly capillaries
with a diameter <6 µm. The acquired images (see Fig. 1 D) were
not 3D reconstructions of z-stacks. These were single focal
planes. In this case, the thickness of image volume depends on
point-spread function (effectively the focal volume) in the z
direction of the excitation laser, which is ∼1 µm for the two-
photon imaging system used.
Calculation of the BBB permeability–surface area product
Data were analyzed as previously reported using a slightly
modified approach (Bell et al., 2010). Time series image stacks
were registered (StackReg, ridged body algorithm) in FIJI (Im-
ageJ; Schindelin et al., 2012), and an ∼400 × 400-µm region of
interest (ROI) was selected from the image sequence for analy-
sis. To determine the fluorescence in the parenchyma over time,
a mask of the vessels in the ROI was made using the Huang
threshold setting in FIJI, and the resulting binary mask was
subtracted from the original ROI image sequence.
The in vivo BBB permeability for FITC-dextran was estimated
as the permeability–surface area product (PS) as we previously
described (Bell et al., 2010; Nikolakopoulou et al., 2019; Deane
et al., 2003) using the following formula:






where Hct is the hematocrit (45%) and Iv is the initial fluores-
cence intensity of the ROI within the vessel, It is the intensity of
the ROI within the brain at time t, and V is the vessel volume,
assuming 1 g of brain is equivalent to 50 cm2.
Brain uptake of Alexa Fluor 555–cadaverine
For intravenous Alexa Fluor 555–cadaverine tracer injection and
detection, mice were anesthetized with ketamine and xylazine
at 180 mg/kg and 10 mg/kg of body weight, respectively, and
50 µl Alexa Fluor 555–cadaverine (1 mg/ml) was injected into
the retro-orbital venous sinus in mice as described previously
(Bell et al., 2012; Montagne et al., 2018). For P8 mice, 40 µl Alexa
Fluor 555–cadaverine (1mg/ml) was injected i.p. Cadaverinewas
allowed to circulate for 20 min in adult mice and 2 h in postnatal
mice, respectively. Mice were then perfused intracardially with
4% PFA in PBS. Eyes from P8 animals were fixed in 4% PFA for
2 h at room temperature before retina isolation in PBS. Brains
were postfixed at room temperature in 4% PFA for 3 h. For ca-
daverine detection, whole brains and isolated retinas (mounted
in PBS) were imaged using a dissecting microscope with an at-
tached fluorescent lamp and a Texas Red filter and subsequently
processed for immunostaining. Cadaverine leakage was quan-
tified by measuring mean fluorescence intensity in re-
constructed 10-μm maximum projection z-stacks from four to
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six randomly selected fields in the cortex from four nonadjacent
sections (∼100 µm apart).
MRI
All MRI scans were performed using our MR Solutions 7T PET
MR system (bore size ∼24 mm, up to 600 mT.m−1 maximum
gradient) and a 20-mm internal diameter quadrature birdcage
mouse head coil. Mice were anesthetized by 1–1.2% isoflurane in
air. Respiration rate (80.0 ± 10.0 breaths per min) and body
temperature (36.5 ± 0.5°C) were monitored during the experi-
ments, as we described previously (Montagne et al., 2018). The
sequences were collected in the following order: T2-weighted
imaging (2D fast spin echo; time repetition [TR]/time echo
[TE], 4,000/26 ms; 32 slices; slice thickness, 300 µm; in-plane
resolution, 100 × 70 µm2) to obtain structural images followed
by a dynamic contrast-enhanced (DCE) protocol for the brain
vessel permeability assessment. Total imaging time was ∼30 min
per mouse.
As previously described (Montagne et al., 2018), the DCE-
MRI imaging protocol was performed coronally within the
dorsal hippocampus region and included measurement of pre-
contrast T1 values using a variable flip angle fast low-angle shot
(FLASH) sequence (flip angle, 5°, 10°, 15°, 30°, and 45°; TE 3 ms,
slice thickness 1 mm, in-plane resolution 60 × 120 µm2), fol-
lowed by a dynamic series of 180 T1-weighted images with
identical geometry and a temporal resolution of 5.1 s (FLASH,
TR/TE, 20/3 ms; flip angle, 15°; slice thickness, 1 mm; in-plane
resolution, 60 × 120 μm2). A bolus dose (140 µl) of 0.5 mmol/kg
gadolinium diethylenetriamine pentaacetic acid (Gd-DTPA di-
luted in saline 1:6) was injected into the tail vein at a rate of
600 µl/min using a power injector. DCE images were collected
within 15 min of the injection.
MRI postprocessing analysis of BBB permeability
to gadolinium
T1 mapping
T1 relaxation times were estimated using the variable flip angle
method, before Gd-DTPA injection, with a series of FLASH im-
ages with varying flip angle and constant TR and TE, as previ-
ously described (Montagne et al., 2018, 2015; Nation et al., 2019;
Montagne et al., 2020).
Ktrans mapping
We determined the capillary permeability transfer constant,
Ktrans, to intravenously injected gadolinium-based contrast agent
in both the dorsal hippocampus and primary somatosensory
cortex using a modified method as we reported in humans with
the postprocessing Patlak analysis (Montagne et al., 2015; Nation
et al., 2019; Montagne et al., 2020). We determined the arterial
input functions (AIFs) in each mouse from the common carotid
artery, as previously reported (Nikolakopoulou et al., 2019;
Montagne et al., 2018). Individual AIF curves are particularly
important for calculating accurately the Ktrans values if blood
flow and volume are influenced by age or a pathological process.
The present Patlak analysis requires that the tracer’s diffu-
sion (Gd-DTPA) across the capillary vessel wall remains uni-
directional during the acquisition time. The total tracer
concentration in the brain tissue, Ctissue (t), can be described as a
function of the vascular concentration CAIF (t), the intravascular
blood volume vp, and a transfer constant Ktrans that represents
the flow from the intravascular to the extravascular space using
the following equation:
Ctissue(t)  Ktrans∫t0 CAIF(τ)dτ + νp · CAIF(t).
Postprocessing of the collected DCE-MRI data was performed
using in-house DCE processing software (Rocketship) im-
plemented in MATLAB version R2019b (Barnes et al., 2015).
Behavioral tests
Burrowing
This was performed as we described previously (Sagare et al.,
2013). To assess burrowing behavior, mice were individually
placed in cages equipped with a burrow made from a 200-mm-
long and 70-mm-diameter tube of polyvinyl chloride plastic with
one end enclosed. The burrow was filled with 200 g of mouse
food pellets, and the mice were allowed to burrow for 2 h right
before the beginning of the dark cycle. The weight of the re-
maining food pellets inside the burrowwas determined to obtain
a measurement of the food amount burrowed.
Nest construction
This was performed as we previously reported (Sagare et al.,
2013; Winkler et al., 2015). 2 h after the beginning of the dark
cycle, the animals were individually placed in clean home cages
with a single nestlet. Nests were assessed the next morning and
evaluated following the five-point scale as we described in detail
(Winkler et al., 2015).
Novel object location
This was performed as we have previously reported (Sagare
et al., 2013; Bell et al., 2010; Nikolakopoulou et al., 2019). Ani-
mals were placed in a 30-cm3 box and allowed to habituate to the
testing area for 10 min. Animals were then placed back in their
cages, and two identical ∼5 × 5-cm objects were placed in the top
left and right corner of the testing area. Animals were allowed to
explore the two objects in the testing area for 5 min before being
returned to their cages. After a 1-h interval, one of the objects
was relocated, and the animals were allowed to explore the
testing area once again for 3 min. After each trial, the testing
area and the objects were thoroughly cleaned with a 70% ethanol
solution. All trials, including habituation, were recorded with a
high-resolution camera, and the amount of time each animal
spent exploring the objects was analyzed. Any animal that pre-
sented a preference for either of the two identical objects, before
replacement with the novel location, was eliminated from the
analysis.
Novel object recognition
This was performed as we have previously reported, with
modifications (Sagare et al., 2013; Bell et al., 2010; Montagne
et al., 2018). Briefly, animals were placed in a 30-cm3 box and
allowed to habituate to the testing area for 10min. Animals were
then placed back in their cages, and two identical ∼5 × 5-cm
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objects were placed in the top left and right corner of the testing
area. Animals were allowed to explore the two objects in the
testing area for 5 min before being returned to their cages. After
a 1-h interval, one of the objects was replaced with a new object
(different shape and color), and the animals were allowed to
explore the testing area once again for 3min. After each trial, the
testing area and the objects were thoroughly cleaned with a 70%
ethanol solution. All the trials, including habituation, were re-
corded with a high-resolution camera, and the amount of time
each animal spent exploring the objects was analyzed. Any an-
imal that presented a preference for either of the two identical
objects, before replacement with the novel object/location, was
eliminated from the analysis.
Statistical analysis
Sample sizes were calculated using nQUERY assuming a two-sided
α-level of 0.05, 80% power, and homogeneous variances for the
two samples to be compared, with the means and common SD for
different parameters predicted from published data and our pre-
vious studies (Montagne et al., 2018; Nikolakopoulou et al., 2019;
Kisler et al., 2017). Data are presented as mean ± SEM as indicated
in the figure legends. For parametric comparison between two
groups, an F test was conducted to determine the similarity in the
variances between the groups that are statistically compared, and
statistical significance was analyzed by Student’s t test. For mul-
tiple comparisons, Bartlett’s test for equal variances was used to
determine the variances between the multiple groups, and one-
way ANOVA followed by Bonferroni’s post hoc test was used to
test statistical significance using GraphPad Prism 8.3.1 software.
Data were tested for normality using the Shapiro–Wilk test. A P
value of less than 0.05 was considered statistically significant. For
behavioral analysis, the power is 99.5% in Fig. 1 and between 95%
and 99.5% in Figs. 2 and 4.
Data and materials availability
All data are available in the main text or supplemental material.
Online supplemental material
Fig. S1 shows an intact BBB and microvascular pattern in
Lrp1lox/lox; Tie2-Cre mice at P8, intact microvascular density in
2-mo-old Lrp1lox/lox; Tie2-Cre mice, and BBB breakdown in 1-mo-
old Lrp1lox/lox; Tie2-Cremice. Fig. S2 shows pericyte and astrocyte
endfeet capillary and MFSD2a and GLUT1 levels in brain capil-
laries in Lrp1lox/lox; Tie2-Cre and littermate controls. Fig. S3 shows
neuronal degeneration in 3-mo-old Lrp1lox/lox; Tie2-Cremice after
endothelial-specific Lrp1 deletion. Fig. S4 shows loss of collagen
IV and hemosiderin deposits in Lrp1lox/lox; Tie2-Cre mice and
additional characterization of reagents used in Fig. 4. Fig. S5
shows reversal of BBB breakdown in Lrp1lox/lox; Tie2-Cre mice
after short-term treatment with the CypA inhibitor cyclosporine
A. Table S1 shows primary and secondary antibodies used for
immunohistochemistry.
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Supplemental material
Figure S1. Intact BBB and microvascular pattern in Lrp1lox/lox; Tie2-Cremice at P8, intact microvascular density in 2-mo-old Lrp1lox/lox; Tie2-Cremice,
and BBB breakdown in 1-mo-old Lrp1lox/lox; Tie2-Cremice. (A) Confocal images of lectin+ endothelial microvascular profiles in the cortex (green) and retina
(red) in 8-d-old (P8) Lrp1lox/lox; Tie2-Cre and Lrp1lox/lox littermate control pups injected intravenously with Alexa Fluor 555–conjugated cadaverine show no BBB
leakage of tracer into the cortex (red) or retina (green). Representative images shown are from three mice per group. Scale bars = 200 µm. (B and C) Mi-
crovascular length (B) and capillary branching points (C) determined in 10-µm-thick cortical tissue sections from P8 Lrp1lox/lox and Lrp1lox/lox; Tie2-Cremice and
expressed per square millimeter of tissue. (D) Microvascular length in the cortex of 2-mo-old Lrp1lox/lox and Lrp1lox/lox; Tie2-Cre mice and expressed per square
millimeter of tissue. (E and F)Quantification of fibrinogen deposits (E) and leakage of Alexa Fluor 555–conjugated cadaverine tracer (F) deposits in the cortex of
1-mo-old Lrp1lox/lox; Tie2-Cre mice compared with Lrp1lox/lox controls. In B–F, data represent mean ± SEM, n = 3–5 mice/group; ns, nonsignificant by Student’s
t test; **, P < 0.01; ***, P < 0.001.
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Figure S2. Additional characterization of Lrp1lox/lox; Tie2-Cremice. (A and B) Representative confocal microscopy images of CD13+ pericytes (magenta) and
lectin+ endothelium (blue) in the cortex of 4-mo-old Lrp1lox/lox; Tie2-Cre and Lrp1lox/lox littermate control mice (A), and quantification of pericyte coverage of brain
capillary (<6 µm in diameter) lectin+ endothelial profiles (B). Scale bar = 25 µm. Mean ± SEM, n = 5 mice/group. (C and D) Representative confocal images of
aquaporin 4+ astrocyte endfeet (green) and lectin+ endothelium (purple) in the cortex of 4-mo-old Lrp1lox/lox; Tie2-Cre and Lrp1lox/lox littermate control mice (C)
and quantification of astrocytic endfeet aquaporin 4+ coverage of brain capillary (<6 µm in diameter) lectin+ endothelial profiles (D). Scale bar = 25 µm. Mean ±
SEM, n = 5 mice/group. (E and F) Representative confocal images of α-syntrophin+ astrocytic endfeet (green) and lectin+ endothelium (purple) in the cortex of
4-mo-old Lrp1lox/lox; Tie2-Cre and Lrp1lox/lox littermate control mice (E) and quantification of astrocytic endfeet α-syntrophin+ coverage of brain capillary (<6 µm
in diameter) lectin+ endothelial profiles (F). Scale bar = 25 µm. Mean ± SEM, n = 5 mice per group. (G and H) Immunoblotting (G) and relative abundance of
endothelial major facilitator superfamily domain–containing protein 2 (MSFD2a) using β-actin as a loading control (H) in isolated brain microvessels from 4-mo-
old Lrp1lox/lox; Tie2-Cremice and Lrp1lox/lox littermate controls. (I and J) Immunoblotting (I) and relative abundance of endothelial glucose transporter 1 (GLUT1)
using β-actin as a loading control (J) in isolated brain microvessels from 4-mo-old Lrp1lox/lox; Tie2-Cremice and Lrp1lox/lox littermate controls. In H and J, mean ±
SEM, n = 3 mice per group. In B, D, F, H, and J, ns, nonsignificant by Student’s t test.
Figure S3. Neuronal degeneration in 3-mo-old Lrp1lox/lox; Tie2-Cre mice after endothelial-specific Lrp1 deletion. (A and B) Quantification of NeuN+
neurons (A) and SMI312+ neurites (B) in the cortex (Ctx) and hippocampus (Hp) of 3-mo-old Lrp1lox/lox; Tie2-Cre and Lrp1lox/lox mice. Mean ± SEM, n = 5 mice/
group. Significance by Student’s t test, *, P < 0.05; **, P < 0.01; ***, P < 0.001.
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Figure S4. Loss of collagen IV and hemosiderin deposits in Lrp1lox/lox; Tie2-Cremice and additional characterization of reagents used in Fig. 4. (A and
B) Immunostaining for collagen IV (CollV; magenta) and fluorescent staining for lectin+ endothelium (green) in the cortex of 2-mo-old Lrp1lox/lox;Tie2-Cre and
Lrp1lox/lox control mice (A), and quantification of collagen IV length on brain capillary (<6 µm in diameter) lectin+ endothelial profiles in these mice (B). Scale bar
= 25 µm. Mean ± SEM, n = 5 mice/group. (C and D) Prussian blue hemosiderin deposits in 2-mo-old Lrp1lox/lox;Tie2-Cremouse and lack of Prussian blue deposits
in Lrp1lox/lox control (C), and quantification of Prussian blue+ hemosiderin deposits in these mice (D). Scale bar = 20 µm. Mean ± SEM, n = 3 mice/group. (E)
Inhibition of Ppia mRNA (encoding CypA) by siPpia, but not siControl, in brain endothelial cells isolated from 2-mo-old Lrp1lox/lox; Tie2-Cre mice. (F) Repre-
sentative immunoblotting of mLRP1 in brain endothelial cells from 2-mo-old Lrp1lox/lox; Tie2-Cremice after adenoviral-mediated reexpression with Ad.mLRP1 but
not control Ad.GFP virus. Significance by Student’s t test; ns, not significant; ***, P < 0.001; ****, P < 0.0001.
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Table S1 is provided online and lists the primary and secondary antibodies used for immunohistochemistry.
Figure S5. Short-term treatment with CypA inhibitor cyclosporine A reverses BBB breakdown in Lrp1lox/lox;Tie2-Cre mice. (A–C) CypA (top, red) and
MMP9 (bottom, red) immunostaining in brain capillary (<6 µm in diameter) lectin+ endothelium (blue) in the cortex of 2-mo-old Lrp1lox/lox control and Lrp1lox/lox;
Tie2-Cremice treated for 7 d with cyclosporine A (see Materials and methods) or vehicle (A), and quantification of CypA (B) and MMP9 (C) fluorescent intensity
in brain capillary lectin+ endothelium in these mice. Scale bar = 10 µm. Mean ± SEM, n = 6–7 mice/group. (D–F) IgG (top, purple) and fibrinogen (bottom,
purple) immunostaining and lectin+ endothelial brain capillary (<6 µm in diameter) profiles (green) in the cortex of 2-mo-old Lrp1lox/lox control and Lrp1lox/lox;
Tie2-Cre mice treated with cyclosporine A or vehicle (D), and quantification of IgG (E) and fibrinogen (F) perivascular capillary deposits in the cortex (Ctx) and
hippocampus (Hp) of these mice. Scale bar = 20 µm. Mean ± SEM, n = 5–6 mice/group. (G) Quantification of ZO-1, occludin, and collagen IV length on lectin+
endothelial capillary profiles in the cortex of 2-mo-old Lrp1lox/lox;Tie2-Cremice treated with cyclosporine A or vehicle compared with Lrp1lox/lox. Mean ± SEM, n =
5 mice/group. In B, C, and E–G, significance was determined by one-way ANOVA followed by Bonferroni post hoc test, *, P < 0.05; ***, P < 0.001; ****, P <
0.0001.
Nikolakopoulou et al. Journal of Experimental Medicine S4








f Edinburgh user on 16 M
arch 2021
